Candel therapeutics reports fourth quarter and full year 2023 financial results and recent corporate highlights

Needham, mass., march 28, 2024 (globe newswire) -- candel therapeutics, inc. (candel or the company) (nasdaq: cadl), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today reported financial results for the fourth quarter and year ended december 31, 2023, and provided a corporate update.
CADL Ratings Summary
CADL Quant Ranking